Skip to main content

Research Repository

Advanced Search

Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke

Gao, Ying; Chen, Weiqi; Pan, Yuesong; Jing, Jing; Wang, Chunjuan; Johnston, S. Claiborne; Amarenco, Pierre; Bath, Philip M.; Jiang, Lingling; Yang, Yingying; Wang, Tingting; Han, Shangrong; Meng, Xia; Lin, Jinxi; Zhao, Xingquan; Liu, Liping; Zhao, Jinguo; Li, Ying; Zang, Yingzhuo; Zhang, Shuo; Yang, Hongqin; Yang, Jianbo; Wang, Yuanwei; Li, Dali; Wang, Yanxia; Liu, Dongqi; Kang, Guangming; Wang, Yongjun; Wang, Yilong

Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke Thumbnail


Authors

Ying Gao

Weiqi Chen

Yuesong Pan

Jing Jing

Chunjuan Wang

S. Claiborne Johnston

Pierre Amarenco

PHILIP BATH philip.bath@nottingham.ac.uk
Stroke Association Professor of Stroke Medicine

Lingling Jiang

Yingying Yang

Tingting Wang

Shangrong Han

Xia Meng

Jinxi Lin

Xingquan Zhao

Liping Liu

Jinguo Zhao

Profile Image

YING LI YING.LI1@NOTTINGHAM.AC.UK
Assistant Professor

Yingzhuo Zang

Shuo Zhang

Hongqin Yang

Jianbo Yang

Yuanwei Wang

Dali Li

Yanxia Wang

Dongqi Liu

Guangming Kang

Yongjun Wang

Yilong Wang



Abstract

BACKGROUND: Dual antiplatelet treatment has been shown to lower the risk of recurrent stroke as compared with aspirin alone when treatment is initiated early (≤24 hours) after an acute mild stroke. The effect of clopidogrel plus aspirin as compared with aspirin alone administered within 72 hours after the onset of acute cerebral ischemia from atherosclerosis has not been well studied. METHODS: In 222 hospitals in China, we conducted a double-blind, randomized, placebo-controlled, two-by-two factorial trial involving patients with mild ischemic stroke or high-risk transient ischemic attack (TIA) of presumed atherosclerotic cause who had not undergone thrombolysis or thrombectomy. Patients were randomly assigned, in a 1:1 ratio, within 72 hours after symptom onset to receive clopidogrel (300 mg on day 1 and 75 mg daily on days 2 to 90) plus aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 21) or matching clopidogrel placebo plus aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 90). There was no interaction between this component of the factorial trial design and a second part that compared immediate with delayed statin treatment (not reported here). The primary efficacy outcome was new stroke, and the primary safety outcome was moderate-to-severe bleeding - both assessed within 90 days. RESULTS: A total of 6100 patients were enrolled, with 3050 assigned to each trial group. TIA was the qualifying event for enrollment in 13.1% of the patients. A total of 12.8% of the patients were assigned to a treatment group no more than 24 hours after stroke onset, and 87.2% were assigned after 24 hours and no more than 72 hours after stroke onset. A new stroke occurred in 222 patients (7.3%) in the clopidogrel-aspirin group and in 279 (9.2%) in the aspirin group (hazard ratio, 0.79; 95% confidence interval [CI], 0.66 to 0.94; P = 0.008). Moderate-to-severe bleeding occurred in 27 patients (0.9%) in the clopidogrel-aspirin group and in 13 (0.4%) in the aspirin group (hazard ratio, 2.08; 95% CI, 1.07 to 4.04; P = 0.03). CONCLUSIONS: Among patients with mild ischemic stroke or high-risk TIA of presumed atherosclerotic cause, combined clopidogrel-aspirin therapy initiated within 72 hours after stroke onset led to a lower risk of new stroke at 90 days than aspirin therapy alone but was associated with a low but higher risk of moderate-to-severe bleeding. (Funded by the National Natural Science Foundation of China and others; INSPIRES ClinicalTrials.gov number, NCT03635749.).

Citation

Gao, Y., Chen, W., Pan, Y., Jing, J., Wang, C., Johnston, S. C., …Wang, Y. (2023). Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke. New England Journal of Medicine, 389(26), 2413-2424. https://doi.org/10.1056/nejmoa2309137

Journal Article Type Article
Acceptance Date Oct 19, 2023
Online Publication Date Dec 28, 2023
Publication Date Dec 28, 2023
Deposit Date Oct 30, 2023
Publicly Available Date Jan 2, 2024
Journal New England Journal of Medicine
Print ISSN 0028-4793
Electronic ISSN 1533-4406
Publisher Massachusetts Medical Society
Peer Reviewed Peer Reviewed
Volume 389
Issue 26
Pages 2413-2424
DOI https://doi.org/10.1056/nejmoa2309137
Keywords Stroke; Transient ischemic attack; Atherosclerosis; Clopidogrel
Public URL https://nottingham-repository.worktribe.com/output/26795227
Publisher URL https://www.nejm.org/doi/full/10.1056/NEJMoa2309137

Files






You might also like



Downloadable Citations